EUVIMEDFaigh amach EUVIMED
CrossrefCárta eolais

An iron-regulated methionine redox axis governs adipose browning and cancer cachexia

Jung Seung Nam, Sung Shin Ahn, Yeonoh Shin, Ariana Vargas-Castillo, Maya S. Dixon, Pardis Ahmadi, Kathrin Schilling, Fereshteh Zandkarimi, Alex Chen, Nal Ae Yoon, Harrison Cullen, Yanping Sun, Thomas C. Caffrey, Kelsey A. Klute, Benjamin J. Swanson, Jordan Lu, Samuel Pan, Yuxuan Chen, Shu Ichimiya, Geena Kim, Jeanine M. Genkinger, Kazuki Sugahara, Michael D. Kluger, Paul Grandgenett, Michael A. Hollingsworth, Luke Berchowitz, Anthony W. Ferrante, Lori M. Zeltser, Sabrina Diano, Iok In Christine Chio

Nature Cancer · 2026-09-22 · 7 (10) · 1514-1532

DOI: 10.1038/s43018-026-01234-y ↗
AchoimreSonraí leabharliosta

Achoimre

Abstract Adipose browning and atrophy are early events of cachexia, a lethal metabolic disorder affecting nearly half of the population with cancer. Here, using individual-derived specimens and mouse models, we identified an iron-dependent pathway that initiates adipose browning in both physiological and cachectic settings. Upon adrenergic stimulation of adipocytes, an influx of iron induces the activity of methionine sulfoxide reductase A (MSRA), an enzyme that reverses the oxidation of proteinaceous methionine residues. Mechanistically, iron coordination by the conserved iron-binding EXXH motif of two MSRA polypeptides serves to dimerize, stabilize and elevate its reductase activity. Iron-bound MSRA dimers in turn promote adipose browning by maintaining the reduced state of select substrates, including the catalytic subunit of protein kinase A. Remarkably, in mouse models, MsrA deletion impairs adipose browning, mitigates cachexia and prolongs the survival of tumor-bearing animals. Thus, as a key nexus of cancer-associated cachexia, the β3 adrenergic receptor–iron–MSRA axis is a promising target for clinical intervention.

Eolas a oireann do do chuid oibre.

Ó thús saor in aisce agus taighde litríochta pearsanta go dtí an Research Suite iomlán.

Féach ar na taraifí →

An bhfuil gach téacs iomlán ó fhoilsitheoirí san áireamh?

Ní hea. Is ábhair éagsúla iad tagairtí bibleagrafaíocha, achoimrí agus lánthéacsanna. Braitheann fáil an lánthéacs ar an bhfoinse, Open Access agus ar na ceadúnais atá agat cheana. Ní chuireann taraif EUVIMED cearta breise foilsitheora ina n-ionad.

Féach ar na taraifí →